Treatment Outcome of the Drug-resistant Zoonotic Cutaneous Leishmaniasis by Glucantime

Soleimanifard, Simindokht; Arjmand, Reza; Saberi, Sedighe; Salehi, Mansoor; Hejazi, Seyed Hossain

Treatment Outcome of the Drug-resistant Zoonotic Cutaneous Leishmaniasis by Glucantime

Document Type : Original Article

Authors

¹ Department of Parasitology, School of Medicine, Isfahan University of Medical Sciences and Health Services, Isfahan, Iran

² Department of Parasitology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

³ Department of Anatomical Sciences and Molecular Biology, Medical School, Isfahan University of Medical Sciences and Health Services, Isfahan, Iran

⁴ Department of Parasitology, School of Medicine, Isfahan University of Medical Sciences and Health Services, Isfahan; Department of Parasitology, Skin Disease and Leishmaniasis Research Center, School of Medicine, Isfahan University of Medical Sciences and Health Services, Isfahan, Iran

Abstract

Background: Resistance of Leishmania species to antimonial drugs has increased. Hence, in the present study Leishmania major isolates were collected from patients with resistance phenotype and the presence/absence of resistance to Glucantime was investigated. Materials and Methods: Samples were taken from 10 cutaneous leishmaniasis (CL) patients who had not responded to chemotherapy with Glucantime. Nested polymerase chain reaction (PCR) was performed to identify the isolated species. Stationary phase promastigotes were added to the grown, adhesive J774 macrophages. Values obtained from standard strain were compared with the test cultures after exposure to the medicine. In vivo, the effects of Glucantime were assessed by comparing the sizes and the parasite burden of the lesions on mouse model. Results: The results of amplified band on agarose gel demonstrated all samples were L. major. After exposure to medicine, a reduction of intracellular amastigotes to half was detected. In vivo, the parasite was eliminated in 90% of mice with lesions caused by both isolates of patients and standard L. major, and their lesions became smaller significantly. Conclusion: Pentavalent antimonial (SbV) salts are the main component of chemotherapy against leishmaniasis. However, the medicine has been found ineffective. In the present study, isolates from patients with no response to treatment had no significant difference from the standard L. major strain (as the sensitive strain). Therefore, in patients with resistance phenotype to Glucantime, the parasites did not actually have intrinsic resistance, i.e., environmental and host factors prevented the successful treatment of the disease.

Keywords

References

1.	van der Meide WF, Jensema AJ, Akrum RA, Sabajo LO, Lai A, Fat RF, Lambregts L, et al. Epidemiology of cutaneous leishmaniasis in Suriname: A study performed in 2006. Am J Trop Med Hyg 2008;79:192-7.
2.	Yaghoobi-Ershadi MR, Jafari A, Hanafi-Bojd AA. A new epidemic focus of zoonotic cutaneous leishmaniasis in central Iran. Ann Saudi Med 2004;24:98-101.
3.	Singh AK, Papadopoulou B, Ouellette M. Gene amplification in amphotericin B-resistant leishmania tarentolae. Exp Parasitol 2001;99:141-7.
4.	Ferreira FM, Castro RA, Batista MA, Rossi FM, Silveira-Lemos D, Frézard F, et al. Association of water extract of green propolis and liposomal meglumine antimoniate in the treatment of experimental visceral leishmaniasis. Parasitol Res 2014;113:533-43.
5.	Beheshti M, Ghotbi S, Amirizade S. Therapeutic and adverse effects of glucantime used for treatment of cutaneous leishmaniasis. Shiraz E-Medical Journal 2007;8155-161
6.	Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006;19:111-26.
7.	Thakur CP, Sinha GP, Pandey AK, Kumar N, Kumar P, Hassan SM, et al. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases. Ann Trop Med Parasitol 1998;92:561-9.
8.	Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med 2006;3:e162.
9.	Mary C, Faraut F, Deniau M, Dereure J, Aoun K, Ranque S, et al. Frequency of drug resistance gene amplification in clinical leishmania strains. Int J Microbiol 2010;2010:pii: 819060.
10.	Salaün P, Frézard F. Unexpectedly high levels of antimony (III) in the pentavalent antimonial drug Glucantime: Insights from a new voltammetric approach. Anal Bioanal Chem 2013;405:5201-14.
11.	Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 2001;6:928-34.
12.	Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001;6:849-54.
13.	Chawla B, Madhubala R. Drug targets in leishmania. J Parasit Dis 2010;34:1-13.
14.	Ashutosh, Sundar S, Goyal N. Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol 2007;56:143-53.
15.	Hadighi R, Boucher P, Khamesipour A, Meamar AR, Roy G, Ouellette M, et al. Glucantime-resistant leishmania tropica isolated from Iranian patients with cutaneous Leishmaniasis are sensitive to alternative antileishmania drugs. Parasitol Res 2007;101:1319-22.
16.	Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J Infect Dis 2006;193:1375-83.
17.	Berman JD, Chulay JD, Hendricks LD, Oster CN. Susceptibility of clinically sensitive and resistant Leishmania to pentavalent antimony in vitro. Am J Trop Med Hyg 1982;31:459-65.
18.	Navin TR, Arana BA, Arana FE, Berman JD, Chajón JF. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992;165:528-34.
19.	Sharifi I, Fekri AR, Aflatonian MR, Nadim A, Nikian Y, Kamesipour A. Cutaneous leishmaniasis in primary school children in the south-eastern Iranian city of Bam, 1994-95. Bull World Health Organ 1998;76:289-93.
20.	Momeni AZ, Jalayer T, Emamjomeh M, Khamesipour A, Zicker F, Ghassemi RL, et al. A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 1999;17:466-72.
21.	Sadeghian G, Ziaei H, Bidabadi LS, Baghbaderani AZ. Decreased effect of glucantime in cutaneous leishmaniasis complicated with secondary bacterial infection. Indian J Dermatol 2011;56:37-9. [PUBMED]
22.	Noyes HA, Reyburn H, Bailey JW, Smith D. A nested-PCR-based schizodeme method for identifying Leishmania kinetoplast minicircle classes directly from clinical samples and its application to the study of the epidemiology of Leishmania tropica in Pakistan. J Clin Microbiol 1998;36:2877-81.
23.	Esmaeili J, Mohebali M, Edrissian GH, Rezayat SM, Ghazi-Khansari M, Charehdar S. Evaluation of mil tefosine against leishmania major (MRHO/IR/75/ER):In vitro and in vivo studies. Acta Medica Iranica 2008;46:191-6.
24.	Mohammadzadeh M, Behnaz F, Golshan Z. Efficacy of glucantime for treatment of cutaneous leishmaniasis in central Iran. J Infect Public Health 2013;6:120-4.
25.	Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, et al. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 1999;180:564-7.
26.	Faraut-Gambarelli F, Piarroux R, Deniau M, Giusiano B, Marty P, Michel G, et al.In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: A study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob Agents Chemother 1997;41:827-30.
27.	Alizadeh R, Hooshyar H, Bandehpor M, Arbabi M, Kazemi F, Talari A, et al. Detection of drug resistance gene in cutaneous leishmaniasis by PCR in some endemic areas of Iran. Iran Red Crescent Med J 2011;13:863-7.
28.	Decuypere S, Rijal S, Yardley V, De Doncker S, Laurent T, Khanal B, et al. Gene expression analysis of the mechanism of natural Sb (V) resistance in Leishmania donovani isolates from Nepal. Antimicrob Agents Chemother 2005;49:4616-21.
29.	Abdo MG, Elamin WM, Khalil EA, Mukhtar MM. Antimony-resistant Leishmania donovani in eastern Sudan: Incidence and in vitro correlation. East Mediterr Health J 2003;9:837-43.
30.	Robledo SM, Valencia AZ, Saravia NG. Sensitivity to Glucantime of Leishmania Viannia isolated from patients prior to treatment. J Parasitol 1999;85:360-6.
31.	Croft SL, Barrett MP, Urbina JA. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol 2005;21:508-12.
32.	Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: A multicenter study. Clin Infect Dis 2003;37:800-4.

Advanced Biomedical Research